首页> 外文期刊>Pharmaceutical statistics. >Sample size re-estimation for survival data in clinical trials with an adaptive design
【24h】

Sample size re-estimation for survival data in clinical trials with an adaptive design

机译:采用自适应设计的临床试验中生存数据的样本量重新估计

获取原文
获取原文并翻译 | 示例
           

摘要

In clinical trials with survival data, investigators may wish to re-estimate the sample size based on the observed effect size while the trial is ongoing. Besides the inflation of the type-l error rate due to sample size re-estimation, the method for calculating the sample size in an interim analysis should be carefully considered because the data in each stage are mutually dependent in trials with survival data. Although the interim hazard estimate is commonly used to re-estimate the sample size, the estimate can sometimes be considerably higher or lower than the hypothesized hazard by chance. We propose an interim hazard ratio estimate that can be used to re-estimate the sample size under those circumstances. The proposed method was demonstrated through a simulation study and an actual clinical trial as an example. The effect of the shape parameter for the Weibull survival distribution on the sample size re-estimation is presented.
机译:在具有存活数据的临床试验中,研究人员可能希望在试验进行期间根据观察到的效应量重新估算样本量。除了由于重新估计样本量而导致的I型错误率膨胀外,还应仔细考虑在中期分析中计算样本量的方法,因为每个阶段的数据在与生存数据的试验中都是相互依赖的。尽管临时危害评估通常用于重新估计样本量,但有时偶然性会比假定的危害高或低得多。我们提出了一种临时危险比估算,可用于在这些情况下重新估算样本量。通过仿真研究和实际的临床试验举例说明了该方法。提出了威布尔生存分布的形状参数对样本大小重新估计的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号